Washington, DC – The Cure Coalition today responded to the U.S.-China Economic and Security Review Commission’s new report exposing significant risks in America’s medical supply chains and research enterprise. The Commission found that a quarter of generic medicines used by Americans rely on key ingredients produced in China, with some essential health products sourced exclusively from Chinese manufacturers. The report warns that similar vulnerabilities extend to medical research and biotechnology, where U.S. scientific progress and drug innovation risk becoming dependent on foreign supply chains.

“America’s health and security are at stake when we rely on China for the essential ingredients, scientific supplies, and innovation that drive our medical breakthroughs,” said Cara Kingan, Executive Director for the Cure Coalition. “We cannot afford to put patients, research, or future cures at risk. National security begins in the medicine cabinet—and in the laboratory—when American medicines and discoveries are made in America.”

The Commission’s report highlights China’s rapid expansion into advanced fields such as synthetic biology, mRNA technology, and genetic research, making China a gatekeeper for the building blocks of tomorrow’s therapies. Many U.S. universities, biotech firms, and medical research centers are dependent on partnerships or supplies linked to China, even as quality concerns persist in foreign manufacturing.

Key points from the Commission’s 2025 report:

· Twenty-five percent of generic drugs taken by Americans rely on key ingredients from China, putting vital products such as blood thinners, cancer treatments and antibiotics at risk of disruption.

· The full extent of U.S. dependence is unclear because FDA lacks the authority and data necessary to track the origin of ingredients and equipment.

· Chinese leadership in synthetic biology, mRNA platform technologies, and biomanufacturing means America’s future medical advances could be vulnerable to foreign control and supply shocks.

· U.S. medical research and drug innovation frequently rely on Chinese partners, reagents, and equipment, exposing scientific progress to risk if supply chains are disrupted.

· The report calls for urgent investment in domestic research infrastructure, biomedical manufacturing, and supply chain transparency to secure American health and innovation.

Cure Coalition Background

The Cure Coalition is a national nonprofit organization dedicated to restoring safety, integrity, and independence to American medical research. Founded in 2025 by patient advocate and medical professional Cara Kingan, the coalition unites families, scientists, and policymakers to demand accountability, strengthen domestic research capacity, and champion ethical innovation that protects the health and future of every child.

###